Gene Signature Can Predict Breast Cancer Responsiveness to New Class of Drugs, Scientists Say

Gene Signature Can Predict Breast Cancer Responsiveness to New Class of Drugs, Scientists Say
Scientists have discovered a gene signature in certain types of breast cancer that can be used to determine the likelihood of these tumors responding to treatment with a new class of anti-cancer medications known as Smac-mimetics. Triple-negative breast cancer (TNBC) was one of the best responders, suggesting these agents may be adopted as a new line of therapy for this difficult-to-treat form of breast cancer in the future, investigators noted. Their findings were reported in the study, “Targeting triple-negative breast cancers with the Smac-mimetic birinapant,” published in the journal Cell Death & Differentiation. Smac-mimetics are a new class of targeted therapies that work by mimicking the effects of naturally-produced Smac proteins. These proteins promote cell death by curbing the activity of inhibitor of apoptosis proteins, which are associated with tumor survival and cancer progression. Some Smac-mimetics, including LCL161 (developed by Novartis) and birinapant (jointly deve
Subscribe or to access all post and page content.